Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Verrica Pharmaceuticals Inc. (VRCA) had Revenue of $14.34M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$14.34M
Net Income	$-0.27M
Cost of Goods Sold	$1.11M
Gross Profit	$13.23M
Operating Expenses	$12.72M
Operating Income	$1.63M
Non-Operating Income/Expense	$-1.90M
Pre-Tax Income	$-0.27M
Normalized Pre-Tax Income	$-0.27M
Income after Taxes	$-0.27M
Income from Continuous Operations	$-0.27M
Consolidated Net Income/Loss	$-0.27M
Normalized Income after Taxes	$-0.27M
EBIT	$1.63M
EBITDA	$1.81M
Weighted-Average Shares Outstanding (Basic)	9.49M
Weighted-Average Shares Outstanding (Diluted)	9.49M
Earnings per Share (EPS) (Basic)	$-0.03
Earnings per Share (EPS) (Diluted)	$-0.03
Balance Sheet Financials
Current Assets	$36.27M
Property, Plant, and Equipment	$0.23M
Long-Term Assets	$4.62M
Total Assets	$40.90M
Current Liabilities	$28.91M
Long-Term Debt	$22.25M
Long-Term Liabilities	$29.03M
Total Liabilities	$57.94M
Common Equity	$-17.04M
Tangible Shareholders Equity	$-17.04M
Shareholders Equity	$-17.04M
Common Shares Outstanding	9.49M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-13.04M
Cash Flow from Investing Activities	$0.00M
Cash Flow from Financial Activities	$-12.20M
Beginning Cash	$46.33M
End Cash	$21.10M
Increase/Decrease in Cash	$-25.23M
Stock-Based Compensation	$2.63M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.25
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	4.27
Debt to Equity Ratio	-2.06
Gross Margin	92.27%
Operating Margin	11.34%
EBIT Margin	11.34%
EBITDA Margin	--
Pre-Tax Profit Margin	-1.91%
Profit Margin	-1.91%
Free Cash Flow	$-13.04M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.35
Inventory Turnover	0.48
Receiveable Turnover	1.96
Days Sales in Receivables	45.99
Return on Equity	1.61%
Return on Tangible Equity	1.61%
Return on Assets	-0.67%
Return on Investments	-5.26%
Book Value Per Share	$-1.80
Free Cash Flow per Share	$-1.37
Operating Cash Flow per Share	$-1.37

Data from Zacks Investment Research, Inc.